 |
|
|
| |
LIVER-DIRECTED TARGETING OF PD-L1 WITH RO7191863, A LOCKED NUCLEIC ACID, IN CHRONIC HEPATITIS B: FIRST REPORT OF PHASE 1 TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS
|
| |
| |
AASLD: THE PHARMACOKINETIC AND SAFETY PROFILES OF RO7445482 siRNA [RG6346] ARE SIMILAR BETWEEN ASIAN AND NON-ASIAN HEALTHY VOLUNTEERS AND CHRONIC HEPATITIS B PATIENTS IN A PHASE 1 STUDY (12/13/21)
AASLD 2021 Nov 12-15
Anna Maria Geretti,1 Edward Gane,2 Karine Lacombe,3 Rozalina Balabanska,4 Gemma Attley,5 Priscila Teixeira,1 Souphalone Luangsay,1 Miriam Triyatni,1 Sijie Lu,6 Spiky Lin,6 Man-Fung Yuen,7 on behalf of the NP40479 Study Group
Roche Innovation Center, Basel, Switzerland; 2Auckland Clinical Studies, Auckland, New Zealand; 3 Saint Antoine Hospital, Paris, France; 4 Acibadem City Clinic Tokuda Hospital, Sofia, Bulgaria; 5Roche Innovation Center, New York, USA; 6Roche Innovation Center, Shanghai, China; 7Queen Mary Hospital, Hong Kong
|
| |
|
|
|
|
|
